Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) gained $0.88 (22%) to $4.86 on Monday after clarifying the regulatory path in the U.S. for Northera droxidopa to treat neurogenic orthostatic hypotension (NOH). Chelsea still plans to submit an NDA next quarter based on efficacy data from two completed Phase III studies, Study 301 and Study 302. Chelsea finished the week up $1.02 (26%) to $5 (see B14).
NicOx S.A. (Euronext:COX) fell €0.46 (20%) to €1.82 on Wednesday after withdrawing an MAA in Europe for naproxcinod for osteoarthritis (OA). The company